New Report on Platelet and Plasma Market with America's Blood Centers, American Red Cross, Blood Centers of America, Brazilian Red Cross

The Platelet and Plasma Market is set to exceed USD 6.5 billion by 2024; according to a new research report by Global Market Insights. Increasing prevalence of chronic diseases such as liver cirrhosis, non-alcoholic steato-hepatitis (NASH) hepatocellular carcinoma and other liver diseases will fuel the market growth during the foreseeable years. Liver diseases are the fifth most common cause of mortality across the world.

According to American Association for the Study of Liver Diseases, in 2014, liver diseases such as alcoholic liver disease, viral hepatitis and nonalcoholic fatty liver disease affected more than 300 million people in China. Geriatric population is susceptible to various liver diseases owing to functional limitations growing with age. Growing cases of liver diseases coupled with rising geriatric population base will stimulate the demand for platelets and plasma for treatment of aforementioned liver diseases thereby augmenting the platelet and plasma market growth.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/2737

The incidence of immune thrombocytopenia among U.S. adults is also quite alarming – approximately 3.3 per 100,000 adults in a year. As per experts’ opinion, platelet transfusion, in the true sense, has brought a disruption in the treatment of hypoproliferative thrombocytopenia. In fact, American Academy of Neurology even claims that plasma can be used for treating various neurological disorders as well. Ergo, it can be stated that platelet and plasma industry’s penetration in the healthcare space has changed the conventional therapeutic model in ways more than one. The aforementioned estimates vividly depict the humongous growth prospect of U.S. platelet and plasma market, which dominated the overall business space in 2017 with 34% of the global share.

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
• America's Blood Centers
• American Red Cross
• Blood Centers of America
• Brazilian Red Cross
• Canadian Red Cross
• European Blood Alliance
• German Red Cross
• Indian Red Cross Society (IRCS)
• Italian Red Cross
• Saudi Red Crescent Authority
• South African Red Cross Society (SARCS)
• Spanish Red Cross

As mentioned above, platelet transfusion has immensely contributed to the revolutionary hypoproliferative thrombocytopenia treatment for patients affected with hematological malignancies and cancer. Undeniably it has left a parallel impact on overall platelet and plasma market share. However, it is worth mentioning that despite the long-term application scope of platelet transfusion, all aspects of their optimal usage have not been exploited yet. Incidentally, this has created novel growth opportunities for research fellows and core companies operating in platelet and plasma market to unlock its potential in unexplored arenas. One such area that is presently grabbing the attention is platelet transfusion in cases of ABO and/or RhD incompatibility.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/2737

Decades back, ABO-incompatibility in platelet transfusion was not considered a hindrance in normal response. In fact, ABO-mismatched platelet transfusion was very much in practice for a long period. However, the issue became apparent when ABO incompatibility between donor and recipient ultimately led to a deterioration in the effectiveness of the transfusion and its adverse impact on the recipient. As per the latest study, ABO- compatible platelet transfusion is claimed to be the safest and most effective approach present today in platelet transfusion practice.

In fact, proper identification of high-risk patients and their treatment by ABO-identical platelets transfusion has shown better results, cite experts. In case of negligible ABO-incompatibility, single donor platelet concentrates or random donor platelets concentrates from A2 “universal” PLT donors might be other alternative approach. These extensive research work coherently validates the underlining expansion of platelet and plasma industry over the recent years. As per estimates, platelets segment having reigned the overall business space in 2017 with USD 3.6 billion revenue, would continue to dominate platelet and plasma market over the ensuing years.

Browse Full Report Details @ https://www.gminsights.com/industry-analysis/platelet-and-plasma-market

Chapter 3. Platelet And Plasma Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2013 – 2024
3.3. Industry ecosystem
3.3.1. Value chain analysis
3.3.2. Distribution channel analysis

3.4. Industry impact forces
3.4.1. Growth drivers
3.4.1.1. Higher number of blood transfusions in Europe
3.4.1.2. Recent advances in therapeutic protein drug development
3.4.1.3. Increasing prevalence of liver diseases in elderly population globally
3.4.1.4. Exclusive use of plasma for treatment of rare diseases in Europe
3.4.1.5. Fair reimbursement in developed countries

3.4.2. Industry pitfalls & challenges
3.4.2.1. Stringent regulatory policies
3.4.2.2. Affordability issue in APAC and Latin America due to high costs

3.5. Growth potential analysis
3.5.1. By component
3.5.2. By application
3.5.3. By distribution channel

Global Market Insights Inc. is a global market research and management consulting company catering to leading corporations, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

Global Market Insights, Inc.
4 North Main Street
Selbyville, Delaware 19975 USA
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email:sales@gminsights.com

This release was published on openPR.